Appointment of Sohanya Cheng
Resignation of Michael Torok
PHILADELPHIA, Oct. 30,
2024 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative immunotherapies, today announced the
appointment of Sohanya Cheng, MBA to the Company's Board of
Directors, effective October 31,
2024. Additionally, Michael
Torok has informed the Board of his intention to step down
as a member, effective October 31,
2024, due to other professional commitments.
"It's a pleasure to welcome Sohanya to our Board," said
Sanford Zweifach, Chair of the
Carisma Board. "Her broad experience in oncology, alongside her
skills in leadership, strategic planning, and commercialization,
will be instrumental as we continue to advance our portfolio and
strengthen our foundation. We are also thankful to Michael for his
valuable service and wish him all the best in his next
chapter."
"I am excited to join Carisma's Board and collaborate with the
management team as the Company advances its mission to deliver
innovative immunotherapies to patients facing serious diseases,"
said Ms. Cheng. "I look forward to sharing my insights and
supporting the Company's strategic goals as it solidifies its
position as a leader in engineered macrophages within oncology and
beyond."
About Sohanya Cheng, MBA
Ms. Cheng brings over 20 years of experience in
biopharmaceutical commercialization and research, with a strong
focus on oncology. She currently serves as the EVP, Chief
Commercial Officer, and Head of Business Development at Karyopharm
Therapeutics. Prior to this, she was Vice President, Head of
Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. Ms.
Cheng also spent over a decade at Amgen in various leadership
roles, including Executive Director, Head of Marketing & Sales
for multiple myeloma and Head of Oncology National Sales,
contributing to the commercialization of key oncology brands. She
holds an MBA from the MIT Sloan School of
Management and both a BSc and MA from the University of Cambridge, UK.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302292071.html
SOURCE Carisma Therapeutics Inc.